BioinvestGPT

BioinvestGPT ApS · Research use only

NCT06087406 (Imvotamab in Moderate to Severe Rheumatoid Arthritis): BVCT ex-ante prediction vs. reported outcome

On 26 Oct 2024, BioinvestGPT's BVCT predicted technical failure and commercial failure for this trial. The 9 Jan 2025 readout is classified on the dashboard as True Negative (TN), a correct prediction. Recorded clinical-benefit conclusion: statistically insignificant and commercially insufficient.

Clinical Trial

NCTID
NCT06087406
Drug Name
Imvotamab
Drug MoA
anti-CD3 anti-CD20 T-cell engager
Drug Modality
bispecific antibody
Drug Class
First-In-Class
Therapeutic Area
Immune System Diseases
Indication
Moderate to Severe Rheumatoid Arthritis
Human Patients
33
Sponsor
IGM Biosciences
Phase
Phase 1

Prediction of , index 1806

Prospective Prediction
Prediction Index
1806
Prediction Date
Commercial Prediction
FAILURE (commercially insufficient clinical benefit in DAS28-CRP or ACR20)
Technical Prediction
FAILURE (statistically maybe significant yet very weak clinical benefit in DAS28-CRP or ACR20 against placebo)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
75 days in advance
Readout Data Interpretation
Imvotamab failed to demonstrate sufficient efficacy and further development discontinued accordingly
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically insignificant and commercially insufficient
Prediction Classification
True Negative (TN)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
A Phase 1b, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Imvotamab in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Failed Prior Therapies
Phase
Phase 1
Status
Terminated
Enrollment
33
Lead sponsor
IGM Biosciences, Inc.
Conditions
Rheumatoid Arthritis; Arthritis, Rheumatoid; Arthritis
Interventions
DRUG: Imvotamab; DRUG: Placebo
Design
Randomized · Parallel · Triple
Primary purpose
Treatment
Start
2023-03-15
Primary completion
2025-02-10
Completion
2025-02-10
Primary outcomes
  • To evaluate the safety and tolerability of imvotamab in participants with moderate to severe rheumatoid arthritis (Up to Week 52)

NCT06087406 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials